AB1144 Good therapeutic response with biologics: remission is reality. data from the austrian bioreg registry

Abstract

BackgroundRemission or at last low disease activity is the aim of drug therapy in patients with chronic inflammatory rheumatic diseases. We evaluated disease activity in patients treated with biologics and using data of the Austrian biologic registry.ObjectivesThe aim of this evaluation was to elucidate disease activity in patients with rheumatoid arthritis (RA), spondyloarthritis (SpA) and psoriatic arthritis (PsA) at baseline and at control-visits every six months after inclusion in BioReg.MethodsData were extracted from the Austrian BioReg registry (bioreg.at) which was initiated in 2009 to document patients treated with one of the biologics approved in Austria. Patients with ongoing biologic therapy as well as biologic-naïve patients starting biologic therapy can be included (baseline, BL). Further documentation is recommended about every six months (V1,V2 up to V11). Meanwhile, 1877 patients (rheumatoid arthritis (RA) n=1046, ankylosing spondylitis (SpA) n=446, psoriatic arthritis (PsA) n=322, other disease n=63) have been documented. Estimation of disease activity is done using DAS-28 as well as RADAI-5 in RA, SASPA in PsA, and BASDAI in SpA.ResultsDAS-28 (median values of BL; V1; V2; V9; V10) of patients with RA are 3,30; 2,51; 2,58; 2,52; 2,49, the respective RADAI-5 values are 3,2; 2,4; 2,2; 2.0; 2,3. BASDAI in patients with SpA were 3,60; 2,61; 2,45; 2,63; 2,20. Median values of inflammation's laboratory markers (ESR in mm/1st hour and CRP in mg/l) were always within the normal range (ESR and CRP in RA 15; 12; 12; 12,5; 14 and 2,0; 2,0; 2,0; 2,0; 2,0; in SpA: 8; 6; 7; 8; 8; and 2,0; 1,4; 1,4; 1,1; 1,0 in PsA 9; 8; 9; 7 (V7); 6 (V8); and 1,6; 1,5; 1,4; 1,9 (V7); 0,8 (V8)).ConclusionsOur data confirm the efficiency of therapy with biologicals. During 5 years of continuous treatment more than half of patients with RA reach and keep remission with a DAS-28 below 2,6 and normal values of ESR and CRP. Also patients with SpA and PsA show similar successful therapeutic response.AcknowledgementsBIOREG is supported by an unlimited industrial grantDisclosure of InterestNone declared

Biologika-Therapien in Österreich. Daten aus dem Österreichischen Biologika-Register BioReg

“…B. in England oder Italien. Österreichs Rheumatologen initiieren -im Vergleich zu europäischen Kollegen -eine biologic (b) DMARD-Therapie bereits bei RA PatientInnen mit hoch moderater Krankheitsaktivität (DAS28 4,43), also im Schnitt bei weniger aktiven PatientInnen, was dann offenbar zu höheren Remissionsraten von mehr als 50 % DAS28-Remission und etwa 30 % RADAI-5 Remission führt [7,18].…”